Tempus AI, Inc. (NASDAQ:TEM) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Tempus AI, Inc. (NASDAQ:TEM) have earned a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $79.3077.

Several research analysts have recently commented on the stock. Piper Sandler dropped their price target on shares of Tempus AI from $105.00 to $80.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 11th. Wall Street Zen downgraded shares of Tempus AI from a “hold” rating to a “sell” rating in a research report on Saturday. HC Wainwright cut their target price on Tempus AI from $98.00 to $89.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Canaccord Genuity Group decreased their price target on Tempus AI from $95.00 to $80.00 and set a “buy” rating for the company in a research note on Monday, December 22nd. Finally, Robert W. Baird began coverage on Tempus AI in a report on Tuesday, February 17th. They set an “outperform” rating and a $59.00 price objective on the stock.

Insider Activity at Tempus AI

In related news, CEO Eric P. Lefkofsky sold 166,250 shares of the firm’s stock in a transaction on Wednesday, January 28th. The stock was sold at an average price of $65.56, for a total value of $10,899,350.00. Following the completion of the transaction, the chief executive officer directly owned 8,941,533 shares of the company’s stock, valued at $586,206,903.48. This trade represents a 1.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Ryan Fukushima sold 9,592 shares of the stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $59.05, for a total transaction of $566,407.60. Following the completion of the transaction, the chief executive officer directly owned 694,354 shares of the company’s stock, valued at $41,001,603.70. This trade represents a 1.36% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 596,035 shares of company stock valued at $37,505,125. 26.27% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Cranbrook Wealth Management LLC acquired a new stake in shares of Tempus AI in the 3rd quarter valued at $25,000. JPL Wealth Management LLC acquired a new position in Tempus AI in the third quarter valued at about $26,000. Los Angeles Capital Management LLC bought a new stake in Tempus AI during the fourth quarter worth about $27,000. GAMMA Investing LLC acquired a new stake in shares of Tempus AI during the third quarter worth approximately $28,000. Finally, Allworth Financial LP raised its stake in shares of Tempus AI by 5,000.0% in the second quarter. Allworth Financial LP now owns 459 shares of the company’s stock valued at $29,000 after acquiring an additional 450 shares during the last quarter. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI Stock Performance

Shares of TEM opened at $53.25 on Friday. The company has a market capitalization of $9.47 billion, a PE ratio of -37.77 and a beta of 5.22. The company has a debt-to-equity ratio of 2.52, a quick ratio of 3.12 and a current ratio of 3.13. The company’s 50 day moving average price is $61.34 and its 200 day moving average price is $73.33. Tempus AI has a 52 week low of $36.22 and a 52 week high of $104.32.

Tempus AI News Roundup

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Beat-and-raise fundamentals — Tempus reported robust Q4 and full‑year 2025 results (strong revenue growth, narrower net loss, positive adjusted EBITDA progression) and issued 2026 guidance that targets revenue growth and a first full‑year adjusted EBITDA inflection, supporting a fundamental recovery case. Why Tempus AI (TEM) Is Down 7.5% After 2025 Results
• Positive Sentiment: Product & commercial catalysts — Launch of an HRD‑RNA oncology algorithm and a partnership with Median Technologies to expand lung cancer screening distribution broaden Tempus’s diagnostic pipeline and addressable market if adoption scales. Tempus AI Deepens Precision Oncology Role With New HRD And Lung Tools
• Positive Sentiment: Institutional support and rebound narrative — Several outlets highlight heavy institutional buying, improving unit economics and analyst upside scenarios, which could limit downside and set up a technical rebound if execution continues. Tempus AI Sold Off After a Beat—But the Rebound Case Is Building
• Neutral Sentiment: Investor event calendar — Management will present at the Morgan Stanley TMT conference (March 3); the fireside chat could provide additional color but is not a guaranteed catalyst. Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference
• Neutral Sentiment: Valuation updates — Some fair‑value and price‑target revisions trimmed upside modestly; analysts still show a range of bullish and cautious views, leaving the story sensitive to near‑term execution. How The Tempus AI (TEM) Investment Story Is Evolving With New Data And Valuation Views
• Negative Sentiment: Analyst downgrades and price‑target cuts — Recent analyst actions (including a notable downgrade reported 2/27 and several target cuts in the prior 24 hours) have intensified selling pressure and weakened sentiment despite the beat. Tempus AI (NASDAQ:TEM) Shares Down 7.4% After Analyst Downgrade
• Negative Sentiment: ESOP shelf registration and dilution risk — Tempus filed a US$343.38M ESOP‑related shelf registration; potential future share issuance tied to employee plans can pressure the stock if investors fear dilution. Why Tempus AI (TEM) Is Down 7.5% After 2025 Results
• Negative Sentiment: Execution, debt and market risk — High leverage, a volatile post‑IPO trading history, elevated beta and lingering execution/valuation concerns make the stock susceptible to outsized moves on negative headlines. Is It Time To Reassess Tempus AI (TEM) After Recent Share Price Weakness?

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.